Checktor Biosciences AG

Antimicrobial resistance (AMR), fed by the overprescription of antibiotics, is fast becoming a global emergency. In the case of gonorrhea, one of the most common sexually transmitted infections, only a single drug remains broadly effective against the disease. Key to limiting the formation and spread of resistant bacteria and the misuse of antibiotics is the development of reliable, effective, accessible, and affordable diagnostic technologies.
We are using our novel molecular diagnostic assay to create an accessible diagnostic test that can detect multiple strains of gonorrhea, and associated AMR, within 15 minutes. We are a team of scientists and engineers with startup experience collaborating with partners worldwide and aiming to enter a rapidly growing market worth over $7 billion.